Health & Fitness
Health and Fitness
Health and Fitness
Wed, February 25, 2009 Zacks Bull and Bear of the Day Highlights: Onyx Pharma, Navigant Consulting, Bristol Myers, Biogen Idec and Strayer Education
CHICAGO--([ BUSINESS WIRE ])--[ Zacks Equity Research ] highlights Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) as the Bull of the Day and Navigant Consulting (NYSE: NCI) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Bristol-Myers Squibb (NYSE: [ BMY ]), Biogen Idec (Nasdaq: [ BIIB ]) and Strayer Education, Inc. (Nasdaq: [ STRA ]).
Full analysis of all these stocks is available at [ http://at.zacks.com/?id=2676 ].
Here is a synopsis of all five stocks:
[ Bull of the Day ]:
Nexavar sales in the fourth quarter of 2008 remained strong for Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX). This is mainly attributed to the market penetration in the liver cancer market, while Nexavar market share in kidney cancer market has stabilized due to heavy competition from Pfizer and Wyeth.
We expect continued Nexavar sales growth in 2009 and over the next several years since the label has expanded to liver cancer. In addition to the US and EU, Nexavar has been approved in South Korea and China for liver cancer.
Nexavar will achieve blockbuster status in 2010. We maintain our Buy rating on Onyx shares with a price target of $45 per share.
[ Bear of the Day ]:
Shares of Navigant Consulting (NYSE: NCI) are trading at 14.8x and 13.8x our 2009 and 2010 EPS estimates, respectively -- an 18% premium to the 2009 peer group average. The company's 2008 acquisition of Chicago Partners has offset revenue and operating income declines in its existing business segments.
Until we see further evidence that NCI can improve utilization rates and operating results in its largest operating segments, we believe that a premium valuation, relative to the peer group average, is unwarranted.
Our price target reflects of multiple of 12.5x our 2009 EPS estimate.
Latest Posts on the Zacks [ Analyst Blog ]:
Bernanke: Recession Ends This Year
Overall, this morning's testimony from the chairman brought no new surprises. Bernanke called things as he saw them while trying to provide an ounce of optimism.
For investors, the chairman's speech is just another data point. Nothing has changed since yesterday and nothing new was presented. Rather, for better or worse, the Fed is moving forward with its previous announced plans. Whether more needs to be done is a subject of debate, but it shouldn't change your investment strategy.
How should you invest? Think conservative, counter-cyclical and defensive. Look at companies that either not directly dependent on a strong economy, such as Bristol-Myers Squibb (NYSE: [ BMY ]) or Biogen Idec (Nasdaq: [ BIIB ]), or those that benefit from a weak economy like Strayer Education, Inc. (Nasdaq: [ STRA ]).
Get the full analysis of all these stocks by going to [ http://at.zacks.com/?id=2649 ].
About the Bull and Bear of the Day
Every day, the analysts at Zacks Equity Research select two stocks that are likely to outperform (Bull) or underperform (Bear) the markets over the next 3-6 months.
About the Analyst Blog
Updated throughout every trading day, the [ Analyst Blog ] provides analysis from Zacks Equity Research about the latest news and events impacting stocks and the financial markets.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks [ "Profit from the Pros" ] e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting [ http://at.zacks.com/?id=2677 ].
About Zacks
Zacks.com is a property of [ Zacks Investment Research ], Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the [ Zacks Rank ], which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.
Visit [ http://www.zacks.com/performance ] for information about the performance numbers displayed in this press release.
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
